Last edition
News about Global Pharma
Vanda Pharmaceuticals Acquires US and Canadian Rights to PONVORY
Vanda Pharmaceuticals Inc. (Vanda) announced that it has acquired US and Canadian rights to PONVORY® (ponesimod) from Actelion Pharmaceuticals Ltd. (Janssen), a Johnson & Johnson Company.
Global Pharma | 12/12/2023 | By Manvi | 296
Natco Pharma Chennai Plant Operations Disrupted Due To Cyclone
After following the required step process and safety measures, the factory operations have been shut down temporarily, the drug firm said in a regulatory filing.
Global Pharma | 12/12/2023 | By Manvi | 540
C-CAR031 is based on a novel GPC3-targeting CAR-T (AZD5851) designed by AstraZeneca using their transforming growth factor-beta receptor II (TGFβRII) dominant negative armoring discovery platform, and is manufactured by AbelZeta in China.
Global Pharma | 12/12/2023 | By Manvi | 438
Dr. Reddy's Laboratories Gets 3 Observations from USFDA for R&D Centre
The company has been issued a Form 483 with three observations, which we will address within the stipulated timeline.
Global Pharma | 11/12/2023 | By Manvi | 998
Cipla Unit Recalls One Lot of Medication in US Due to Seal Integrity Issue
Drug major Cipla said its subsidiary is voluntarily recalling one lot of medication in the US due to seal integrity issues.
Global Pharma | 11/12/2023 | By Manvi | 538
Indoco Remedies Receives Tentative ANDA Approval from USFDA for Canagliflozin Tablets
This product will be manufactured by Indoco Remedies Limited, at their manufacturing facility located at Goa (Plant-I) in India.
Global Pharma | 07/12/2023 | By Manvi | 582
Under the terms of the Agreement, Coya has granted Dr. Reddy’s an exclusive license to commercialize COYA 302, a proprietary co-pack kit containing combination of low dose IL-2 and CTLA-4 Ig (abatacept) in the United States, Canada, the European Union and the United Kingdom for ALS.
Global Pharma | 07/12/2023 | By Manvi | 761
Sun Pharma Subsidiary Signs Licensing Agreement with Biopharma Company Aclaris Therapeutics
As per the licensing agreement, Aclaris has granted exclusive rights to Sun Pharma under certain patents for the use of deuruxolitinib, Sun Pharma's JAK inhibitor, or other isotopic forms of ruxolitinib, to treat alopecia areata (AA) or androgenetic alopecia (AGA).
Global Pharma | 06/12/2023 | By Manvi | 725
AIT Worldwide Logistics Acquires British Pharma Shipment Specialist
Supply chain solutions provider AIT Worldwide Logistics has acquired the British pharmaceutical freight forwarder Mach II Shipping Ltd., the company said.
Global Pharma | 06/12/2023 | By Manvi | 1046
MAHE's Centre for cGMP, Manipal Bags India Pharma Awards 2023 for Excellence in Quality Assurance
MAHE Manipal achieved a significant milestone of being awarded the prestigious INDIA PHARMA AWARDS 2023 on Day 1 of CPHI-PMEC India.
Global Pharma | 06/12/2023 | By Manvi | 690
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy